| abstract |
Use of specific cyclolignans for treating insulin-like growth factor-1 receptor (IGF-1R) dependent diseases by inhibiting the insulin-like growth factor-1 receptor is disclosed, wherein the carbon atoms in positions 9 and 9' of these cyclolignans have cis configuration. Specific cyclolignans such as picropodophyllin can be used for the treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. |